Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin

Cancer Research

Volumn 60, Issue 11, 2000, Pages 3105-3112

  Reubi, Jean Claude ^a   Läderach, Ursula ^a   Waser, Beatrice ^a   Gebbers, Jan O ^b   Robberecht, Patrick ^c   Laissue, Jean A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Pathologische Institut am Kantonsspital Luzern   (Switzerland)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ARTICLE; CANCER GENETICS; CANCER INHIBITION; ENDOMETRIUM CARCINOMA; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LEIOMYOMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL;

ADRENAL GLAND NEOPLASMS; ADRENAL MEDULLA; AUTORADIOGRAPHY; BREAST; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEIOMYOMA; LYMPH NODES; MALE; NEOPLASMS; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PEPTIDES; PHEOCHROMOCYTOMA; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, PITUITARY HORMONE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; STOMACH; STOMACH NEOPLASMS;

EID: 18144453553     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Reubi, J. C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J. Nucl. Med., 36: 1846-1853, 1995.
2. Reubi, J. C., Waser, B., Laissue, J. A., and Gebbers, J-O. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res., 56: 1922-1931, 1996.
3. Reubi, J. C., Zimmermann, A., Jonas, S., Waser, B., Läderach, U., and Wiedenmann, B. Regulatory peptide receptors in human hepatocellular carcinomas. Gut, 45: 766-774, 1999.
4. Reubi, J. C., Waser, B., Schmassmann, A., and Laissue, J. A. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin, and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located? Int. J. Cancer, 81: 376-386, 1999.
5. Virgolini, I., Raderer, M., Kurtaran, A., Angelberger, P., Banyai, S., Yang, Q., Li, S., Banyai, M., Pidlich, J., Niederle, B., Scheithauer, W., and Valent, P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med., 331: 1116-1121, 1994.
6. Moody, T. W., Zia, F., Draoui, M., Brenneman, D. E., Fridkin, M., Davidson, A., and Gores, I. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. USA, 90: 4345-4349, 1993.
7. Maruno, K., Absood, A., and Said, S. I. Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in viro. Proc. Natl. Acad. Sci. USA, 95: 14373-14378, 1998.
8. Harmar, A. J., Arimura, A., Gozes, I., Journot, L., Lahurthe, M., Pisegna, J. R., Rawlings, S. R., Robberecht, P., Said, S. I., Sreedharan, S. P., Wank, S. A., and Waschek, J. A. International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev., 50: 265-270, 1998.
9. Gourlet, P., Vandermeers, A., Vertongen, P., Rathe, J., DeNeef, P., Cnudde, J., Waelbroeck, M., and Robberecht, P. Development of high affinity selective VIP1 receptor agonists. Peptides, 18: 1539-1545, 1997.
10. 2 receptor subclass. Peptides, 18: 403-408, 1997.
11. Robberecht, P., Woussen-Colle, M. C., Vertongen, P., de Neef, P., Hou, X., Salmon, I., and Brotchi, J. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors. Peptides, 15: 661-665, 1994.
12. Robberecht, P., Vertongen, P., Velkeniers, B., de Neef, P., Vergani, P., Raftopoulos, C., Brotchi, I., Hooghe-Peters, E. L., and Christophe, J. Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas. J. Clin. Endocrinol. Metab., 77: 1235-1239, 1993.
13. Vertongen, P., Devalck, C., Sariban, E., De Laet, M. H., Martelli, H., Paraf, F., Helardot, P., and Robberecht, P. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas. J. Cell. Physiol., 767: 36-46, 1996.
14. Oka, H., Jin, L., Reubi, J., Qian, X., Scheithauer, B., Fujii, K., Kameya, T., and Lloyd, R. Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. Am. J. Pathol., 153: 1787-1796, 1998.
15. Jiang, S., Kopras, E., McMichael, M., Bell, R. H., Jr., and Ulrich, C. D., II. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res., 57: 1475-1480, 1997.
16. Reubi, J. C., Kvols, L. K., Waser, B., Nagorney, D., Heitz, P. U., Charboneau, J. W., Reading, C. C., and Moertel, C. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res., 50: 5969-5977, 1990.
17. Reubi, J. C., Mazzucchelli, L., and Laissue, J. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology, 106: 951-959, 1994.
18. 17) vasoactive intestinal peptide binding sites in the rat brain. Neuroscience, 23, 539-565, 1987.
19. Hashimoto, H., Ogawa, N., Hagihara, N., Yamamoto, K., Imanishi, K., Nogi, H., Nishino, A., Fujita, T., Nagata, S., and Baba, A. Vasoactive intestinal polypeptide and pituitary adenylate-cyclase activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol. Pharmacol., 52: 128-135, 1997.
20. Dautzenberg, F. M., Mevenkamp, G., Wille, S., and Hauger, R. L. N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. J. Neuroendocrinol., 11: 941-949, 1999.
21. Reubi, J. C., Horisberger, U., Kappeler, A., and Laissue, J. A. Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. Blood, 92: 191-197, 1998.
22. Ottaway, C. A., Lay, T. E., and Greenberg, G. R. High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes. J. Neuroimmunol., 29: 149-155, 1990.
23. Uchida, D., Tatsuno, I., Tanaka, T., Hirai, A., Saito, Y., Moro, O., and Tajima, M. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type I receptor. In: W. G. Forssmann and S. I. Said (eds.), VIP, PACAP, and Related Peptides. Third International Symposium, Vol. 865, pp. 253-258. New York: The New York Academy of Sciences, 1998.
24. Thakur, M. L., Marcus, C. S., Saeed, S., Pallela, V., Minami, C., Diggles, L., Pham, H. L., Ahdoot, R., and Kalinowski, E. A. TC-99M labeled vasoactive intestinal peptide (VIP) analog for imaging tumors in humans. J. Nucl. Med., 40 (Suppl.): 243P, 1999.
25. Krenning, E. P., Kooij, P. P. M., Pauwels, S., Breeman, W. A., Postema, P. T., De Herder, W. W., Valkema, R., and Kwekkeboom, D. J. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion, 57 (Suppl. 1): 57-61, 1996.
26. Otte, A., Mueller-Brand, J., Dellas, S., Nitzsche, E. U., Herrmann, R., and Maecke, H. R. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet, 351: 417-418, 1998.
27. Lilling, G., Wollman, Y., Goldstein, M. N., Rubinraut, S., Fridkin, M., Brenneman, D. E., and Gozes, I. Inhibition of human neuroblastoma growth by a specific VIP antagonist. J. Mol. Neurosci., 5: 231-239, 1994.
28. Zia, H., Hida, T., Jakowlew, S., Birrer, M., Gores, Y., Reubi, J. C., Fridkin, M., Gozes, I., and Moody, T. W. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res., 56: 3486-3489, 1996.
29. Zia, F., Fagarasan, M., Bitar, K., Coy, D. H., Pisegna, J. R., Wank, S. A., and Moody, T. W. Pituitary adenylate cyclase-activating peptide receptors regulate the growth of non-small cell lung cancer cells. Cancer Res., 55: 4886-4891, 1995.